Site-Specific Polypeptide Conjugation via pH and Alcohol Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for stabilizing peptide drugs through non-specific binding of non-peptidyl polymers, such as PEG, often reduce their activity and increase molecular weight, leading to reduced titers and potential side effects due to non-specific binding.
Innovation Solution
A site-specific method for preparing physiologically active polypeptide conjugates by adjusting the pH and alcohol content in the reaction medium to enable site-specific binding of non-peptidyl polymers to target sites on the polypeptide, maintaining activity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PEG is used to stabilize peptide drugs through non-specific binding, then the peptide resistance to kidney loss and enzymatic hydrolysis is improved, but the molecular weight increases significantly and the peptide activity is reduced
Solution Approach 1:
The patent applies local quality by enabling PEG to bind specifically to certain sites on the peptide molecule rather than non-specifically throughout. The site-specific conjugation method ensures that PEG attaches only to designated residues (such as lysine or N-terminal amino groups), leaving other functional regions of the peptide untouched and active. This localized modification approach maintains peptide activity while achieving stabilization.
Solution Approach 2:
The patent utilizes parameter changes by controlling reaction conditions (pH, temperature, PEG molecular weight selection) to optimize the conjugation process. By adjusting these parameters, the method achieves site-specific binding with controlled degrees of substitution, thereby balancing the stabilization benefit against the preservation of peptide activity and avoiding excessive molecular weight increase.
2Duration of action of stationary object
If PEG molecular weight is increased to prolong in-vivo residence time, then the peptide stability is improved, but the peptide titer is significantly reduced
Solution Approach 1:
The patent applies parameter changes by carefully selecting and controlling the molecular weight of PEG used in conjugation. Rather than using high molecular weight PEG that would excessively increase overall conjugate size and reduce titer, the method employs optimally sized PEG chains that provide sufficient stabilization while minimizing impact on peptide concentration and activity.
3Reliability
If non-specific binding of PEG is used to increase molecular weight, then the peptide stability is improved, but the active domain may be shielded and activity lowered
Solution Approach 1:
The patent implements local quality by directing PEG attachment to specific, predetermined sites on the peptide structure. This site-specific conjugation ensures that PEG modifies only certain residues while leaving the active domain and other critical functional regions accessible and unchanged, thereby preventing shielding effects that would reduce activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for high-yield production of conjugates with enhanced stability and activity, reducing the need for frequent administration and minimizing side effects, while maintaining the peptide's physiological activity.
Implementation Method 1
subjecting to a reaction of a physiologically active polypeptide and a non-peptidyl polymer in a reaction medium which contains a specific amount of an alcohol and has a specific pH to enable the non-peptidyl polymer to bind to a target site of the physiologically active polypeptide
Implementation Method 2
isolating and purifying the physiologically active polypeptide conjugate from the reaction mixture of step (i) by ion exchange chromatography using an alcohol
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention provides a method for preparing a site-specific physiologically active polypeptide conjugate in a high yield by treating a physiologically active polypeptide with a non-peptidyl polymer in the presence of an alcohol at a specific pH, which can be desirably employed in the development of long acting formulations of various peptide drugs having high in-vivo activity and markedly prolonged in-blood half-life.